Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder
New data set from Phase 2 clinical trial presented at the Annual Scientific Meeting of the College on Problems of Drug Dependence and published online in JAMA PsychiatryMontreal, Canada, 22 June 2017 — Phase 2 clinical trial data demonstrate that long-acting buprenorphine (CAM2038), a novel subcutaneous buprenorphine depot formulation, produces an immediate and sustained blockade of opioid effects and suppression of withdrawal symptoms in adults with opioid use disorder. Data from the Opioid Challenge Study were presented today at the annual scientific meeting of the College on Problems of